On Air Now

Current Show

Coast to Coast AM   12:00 AM - 5:00 AM

Call Coast to Coast now at 1-800-825-5033

Show Info »

Upcoming Shows

Program Schedule »

Listen

Listen Live Now » 590 AM Kalamazoo, MI

Weather

Current Conditions(Kalamazoo,MI 49001)

More Weather »
63° Feels Like: 63°
Wind: NNW 12 mph Past 24 hrs - Precip: 0.12”
Current Radar for Zip

Tonight

Cloudy 60°

Tomorrow

Partly Cloudy 70°

Tues Night

Clear 51°

Alerts

New Roche breast cancer drug wins backing in Europe and Japan

LONDON (Reuters) - Roche's new breast cancer drug Kadcyla was approved in Japan on Friday and recommended for approval in Europe, building on February's U.S. green light for the product.

Kadcyla is designed for patients with late-stage disease whose cancer cells contain increased amounts of a protein known as HER2.

It works by attaching Herceptin to a drug called DM1, developed by ImmunoGen, which interferes with cancer cell growth. ImmunoGen will receive a $5 million milestone payment from Roche following the Japanese approval.

The European Medicines Agency (EMA) said on Friday its experts had also recommended a prostate cancer medicine, Xofigo, from Algeta and Bayer, which is also already approved in the United States.

In addition, the EMA issued positive recommendations for Johnson & Johnson's diabetes drug Invokana, Gilead's HIV treatment Viteka, GlaxoSmithKline's lung drug Relvar, AstraZeneca's flu vaccine Fluenz Tetra, Novo Nordisk's hemophilia drug NovoEight, Otsuka's schizophrenia drug Abilify Maintena and a premature ejaculation therapy from Plethora Solutions.

Recommendations for marketing approval by the EMA's Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the European Commission within a couple of months.

(Reporting by Ben Hirschler; editing by Keith Weir and Elaine Hardcastle)

Comments